An introduction is presented in which the editor discusses topics including the use of Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in treating type 2 diabetes, the symptoms of gastrointestinal (GI) tract disorders, and the effects of GLP-1 on the physiology.